Salbutamol powder inhaled from the Diskhaler compared to salbutamol as nebulizer solution in severe chronic airways obstruction  by Hansen, N.C.G. & Andersen, P.B.
Respiratory Medicine (1995) 89, 175-l 79 
Salbutamol uowder inhaled from the Diskhaler 
compared to salbutamol as nebulizer solution in severe 
chronic airways obstruction 
N. C. G. HANSEN* AND P. B. ANDERSEN 
Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark 
The bronchodilatory effect of four doses of salbutamol powder (1.6 mg) from a multi-dose dry powder inhaler, 
the Diskhaler, was compared to the effect of 2.5 ml salbutamol nebulizer solution (1 mg ml ‘) from a jet 
nebulizer, Pari Inhalierboy, in a randomized, double-blind, double-dummy, cross-over study performed on 
2 consecutive days. Thirty-two patients with severe chronic obstructive pulmonary disease (COPD), a 
mean FEV, =29% of predicted value, and at least a 15% increase in FEV, after inhaling 5 mg nebulized 
terbutaline were included. Twenty-eight patients were evaluated: 17 women and 11 men with a mean age of 
67 years (range 53-82 years). The mean increases in FEV, were greater after inhalation via the Diskhaler, 
although there was no difference in the patients’ subjective assessment of the treatments. The powder inhaler 
was also effective in patients with the lowest baseline FEV, and the lowest inspiratory peak flow through the 
inhaler. The study demonstrates that dry powder inhalation of salbutamol via a Diskhaler is at least as 
effective as inhalation of salbutamol via a jet nebulizer in providing bronchodilation in patients with 
severe COPD. 
Introduction 
Inhaled bronchodilators may be delivered by a 
variety of methods. During the 1980s domiciliary 
nebulizer treatment with bronchodilators became 
increasingly popular (1). In patients with chronic 
obstructive pulmonary disease (COPD), it has been 
shown that domiciliary nebulizer therapy with 
&-adrenoceptor agonists can be matched by a con- 
ventional pressurized metered dose inhaler (MDI) if 
the correct inhalation technique is used and if equi- 
potent doses are inhaled (2,3). The problem with 
MDIs however, is that about 50% of the patients are 
unable to achieve the correct inhalation technique 
(4). Furthermore, MDIs use chlorofluorocarbons as 
propellants, which when released, contribute to 
atmospheric pollution. 
Multi-dose dry powder inhalers have been devel- 
oped to overcome the disadvantages of the MDIs. 
They are breath-operated and so dispense the need 
for actuation-inspiration co-ordination, they are 
easy to use (5) and contain no chlorofluorocarbons. 
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The replacement of nebulizers with multi-dose dry 
powder inhalers would obviously be advantageous 
both for the patient, in terms of ease of use and 
portability, and for the Local Health Service, in terms 
of reducing resources spent on inhalation treatment. 
In two previous studies, we compared the bron- 
chodilator effects of a dry powder inhaler with high 
resistance against airflow, the Bricanyl Turbuhaler, 
and a jet nebulizer, the Pari Inhalierboy, in patients 
with severe COPD. This showed that the dry powder 
inhaler could match the nebulizer (6,7). 
In the present study, we tested whether 1.6 mg 
salbutamol powder inhaled from a dry powder 
inhaler with low resistance against airflow, the Disk- 
haler, would be equipotent to 2.5 mg salbutamol 
inhaled from a jet nebulizer, in patients with severe 
COPD. The Diskhaler is a multi-dose dry powder 
inhaler designed to be clinically equivalent to the 
single-dose Rotahaler (8). The Ventolin Diskhaler 
dispenses microfine dry powder formulations of 
salbutamol, (200 or 400 pg), contained in blisters on 
an eight-dose Rotadisk. The salbutamol is mixed 
with lactose powder as a carrier substance. The Pari 
Inhalierboy nebulizer was chosen for this study as it 
was the type of nebulizer most frequently used for 
domiciliary treatment in Denmark. From previous 
studies (6,9), we estimated that the bronchodilator 
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effect of 1.6 mg salbutamol from the Diskhaler 
would be equivalent to 2.5 mg salbutamol from the 
nebulizer. 
Materials and Methods 
Thirty-two patients with COPD (defined according 
to the American Thoracic Society criteria (10)) were 
recruited to this study. All the participants were in a 
stable phase of this disease and had remained 
exacerbation-free during the 2 weeks preceding com- 
mencement of the trial. Informed consent was 
obtained from each patient prior to the start of the 
study, which was approved by the local ethics 
committee. 
All the patients had demonstrated a forced expira- 
tory volume in 1 s (FEV,) 150% of the predicted 
value at the previous visit (reference values as recom- 
mended by the Danish Thoracic Society) and showed 
an increase of at least 15% over baseline FEV, 
following inhalation of 5 mg nebulized terbutaline 
during the previous 3 months. Patients with severe 
systemic diseases or with severe lung diseases other 
than COPD were excluded, as were those receiving 
long-term domiciliary oxygen treatment. In addition, 
any patient who was considered unlikely or unable to 
co-operate with the study protocol was considered 
ineligible. 
This was a single-centre, randomized, double- 
blind, double-dummy, cross-over study performed on 
2 consecutive days. On each of the 2 days, patients 
received either 1.6 mg salbutamol(4 x 400 ug) from a 
Diskhaler together with 2.5 ml isotonic saline from a 
jet nebulizer (Pari Inhalierboy), or 2.5 ml salbutamol 
nebulizer solution (1 mg ml ~ ‘) from the nebulizer 
together with four doses of lactose powder from the 
Diskhaler. The nebulizer was used with a face mask. 
The doses were divided into two halves in order to 
study a possible relationship between dose and effect. 
On the 2 study days at the same time in the 
morning, baseline FEV,, forced vital capacity (FVC), 
peak expiratory flow (PEF), forced expiratory flow at 
25, 50 and 75% of FVC (FEFZSYOrvC, FEFSOO,OFvC, 
FEF 75%FvC), and peak inspiratory flow (PIF) were 
recorded by a pneumotachograph (Vitalograph 
Compact). Prior to baseline tests, patients discon- 
tinued their use of all oral bronchodilatory drugs for 
12 h, inhaled anti-cholinergics for 6 h and inhaled 
/3,-agonists for 4 h. 
At 0 min, the patient began the first inhalation 
session inhaling two doses via the Diskhaler and 50% 
of the nebulizer solution. Expiratory flow-volume 
curves were recorded 40 min after the start of this 
first session. At 45 min, the patient began the second 
inhalation session, by inhaling the two remaining 
doses from the Diskhaler and the remaining nebulizer 
solution (until dryness). Expiratory flow-volume 
curves were recorded again 40 and 100 min later (at 
85 and 145 min). 
During the four inhalations through the Diskhaler, 
the patients’ inspiratory flow-volume curve was 
recorded by a serially-connected pneumotachograph 
(Vitalograph MD1 Compact). The weight loss of the 
powder inhaler itself was determined by an electronic 
balance. The accumulated output from the nebulizer 
was continuously estimated by a computer pro- 
gramme during inhalations. The basis for this 
calculation was the multiplication of the previously 
measured output rate by the elapsed activation time 
(the Pari Inhalierboy is activated by the patient only 
during inhalation). The actual output was deter- 
mined as the weight loss of the nebulizing chamber 
(including the face mask) following both inhalation 
sessions. 
At the end of each of the 2 study days, without 
knowing the results of the spirometry, the patients 
assessed the success of the treatment according to a 
seven-point rating scale. This scale ranged from 7, 
‘extraordinarily improved’ to 1, ‘worse’. 
It was calculated that a sample of 32 patients was 
required to distinguish a 40 ml difference between the 
maximal increases in FEV, after both types of treat- 
ment, with a 5% risk of a type 1 statistical error and 
90% statistical power. There was no evidence of a 
carry-over effect between the study days or of any 
effect of time (period effect) when the data were 
analysed (1 l), so paired statistical tests were applied. 
The scores for subjective effects were compared by 
non-parametric tests. The possibility of a Gaussian 
distribution of the remaining study variables could 
not be excluded by Kolmogorov-Smirnov Goodness 
of Fit Test, and parametric tests were used for data 
analysis. 
Results 
Four of the 32 patients were withdrawn from the 
study, three due to a difference in baseline FEV, 
between the study days of more than 20% of the 
average value, and one because the patient took an 
inhaled bronchodilator within 4 h of the second 
visit. Twenty-eight patients completed the study, 17 
women and 11 men with a mean age of 67 years 
(range 53-82 years). The results of the baseline 
spirometry are shown in Table 1. 
Both salbutamol from the Diskhaler and salbuta- 
mol from the nebulizer caused statistically significant 
increases in FEV, over baseline values at 40, 85 and 
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Table I Baseline spirometry on first study day (n=28) 
Mean SD Range 
FEV, (1) 0.73 0.28 0.361.43 
FEV, (% predicted) 29 10 13-52 
FVC (1) 2.05 0.60 1.09-3.19 
FVC (% predicted) 61 16 39-98 
FEVJFVC (%) 36 9 23-65 
PEF (lmin-‘) 156 54 60-250 
FEF,,,,,, (1 min - ‘) 42 23 13-98 
FEF 5whoFVC (1 min - ‘1 19 9 9943 
FEF,,,,,, (1 min - ‘) 9 4 5-17 
PIF (1 min - ‘) 114 45 53-220 
Table 2 Increase in FEV, after inhalation of salbutamol 
from the nebulizer (2.5 mg) and from the powder inhaler, 
expressed as percentage increase over baseline value (n = 28) 
Pari Inhalierboy Diskhaler 
Time? 
2.5 mg salbutamol 1.6 mg salbutamol 
(min) Mean SEM Mean SEM P* 
40 18.3 2.6 21.0 2.7 0.187 
85 21.1 2.4 26.4 2.6 o+lO9 
145 20.0 2.8 27.1 2.9 00l2 
*Paired r-test. TInhalation of first half dosage began at 
0 min, inhalation of second half began at 45 min. 
145 min (PcO.001, paired t-tests). The salbutamol 
powder from the Diskhaler caused greater increases 
in FEV, and the differences between treatments were 
statistically significant at 85 and at 145 min (Table 2). 
Most of the bronchodilator response was obtained 
after the first inhalation session. The increase in 
FEV, over the 40 min value after the second inha- 
lation session was greatest for the powder inhaler, 
but the difference did not reach statistical significance 
(PzO.257 at 85 min, P=O.O54 at 145 min, paired 
t-tests). 
Increases in FVC, PEF, FEF,,,,,,, FEF,,,,,,, 
and FEF750,0Fvc were also greater with the powder 
inhaler. The standard deviations of these variables 
were relatively greater, and only some of the differ- 
ences were statistically significant and only after the 
second inhalation session. 
Twelve patients had no preference for either treat- 
ment, nine patients preferred the Diskhaler and seven 
patients preferred the nebulizer (P=O.8036, binomial 
test). The median subjective score was the same for 
both treatments (Table 3). 
The mean total output from the nebulizer was 
1.5 ml (range 1.25-l-85 ml) corresponding with 
Table 3 Patients subjective assessment of improvement in 
breathing after treatment 
Active treatment 
Diskhaler Pari Inhalierboy 
Extraordinarily improved 3 2 
Much improved I 9 
Somewhat better 10 10 
Only slightly better 5 3 
Very little improvement 2 3 
No better at all 1 1 
Worse 0 0 
Median 5.0 5.0 
Table 4 Peak inspiratory flow (1 min- ‘) through the 
Diskhaler at each of the salbutamol inhalations (n=28) 
Inhalation No. 
Average of four 
1 2 3 4 inhalations 
Mean (group) 63 69 70 71 68 
SD 23 19 24 22 21 
Minimum 32 34 31 37 37 
Maximum 107 107 113 118 105 
1.5 mg salbutamol. The mean fraction nebulized dur- 
ing the first inhalation session was 47% (range 
37-56%) of the total. The mean quantity of active 
drug inhaled from the powder inhaler was 1.1 mg 
(range 06-1.4 mg). The mean fraction inhaled during 
the first inhalation session was 45% (range 29-55%). 
The mean peak inspiratory flow (PIF) rates 
obtained with inhalations through the Diskhaler 
are given in Table 4. The PIF best correlated with 
the baseline PEF value (r=0.5544, P=O.O022) in 
comparison with other expiratory parameters. 
In Fig. 1, FEV, increases at 145 min as percentage 
increase over baseline value are plotted against the 
PIFs through the Diskhaler (average of four inha- 
lations). There was no correlation between the PIF 
through the Diskhaler and the increase in FEV,. 
In Fig. 2, the increase in FEV, at 145 min follow- 
ing treatment with the nebulizer has been subtracted 
from the increase in FEV, following treatment with 
the Diskhaler, in order to standardize according to 
the reversibility of the bronchial obstruction in each 
patient. This difference in FEV, increase (percentage 
increase over baseline value) has been plotted against 
the PIF through the Diskhaler. There was no statis- 
tically significant correlation between the standard 
bronchodilator response and PIF. Similarly, there 
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Fig. I FEV, increase after salbutamol inhalation from the Diskhaler (percentage over baseline at 145 min) plotted against 
PIF through the device (average of four inhalations). 
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Fig 2 Standardized FEV, increase after salbutamol inhalation (percentage over baseline value at 145 min): increase after 
Diskhaler minus increase after nebulizer plotted against PIF through the Diskhaler. 
were no significant correlations between the 
standardized bronchodilator response and the 
baseline FEV,, FVC or PEF (not shown). 
Discussion 
The present study found that 1.6 mg salbutamol 
(4 x 400 pg) administered via a Diskhaler caused 
better bronchodilation on average, than 2.5 mg 
salbutamol inhaled via a face mask from the Pari 
Inhalierboy, in this group of patients with severe 
COPD. Although the formal salbutamol dose from 
the nebulizer was higher than the formal dose from 
the powder inhaler, the Diskhaler is likely to have 
delivered a higher dose to the patients’ lungs. The 
mean weight loss of the nebulizer was 59% of the 
2.5 ml salbutamol solution filled into the nebulizing 
chamber. However, some of this weight loss was due 
to evaporation and the aerosolized salbutamol dose 
was less than 1.5 mg. Loss of aerosol due to leakage 
from the face mask (caused by exhalation during 
nebulization) has resulted in an even smaller salbuta- 
mol dose reaching the patient, but the exact dose 
cannot be estimated. On the contrary, all the powder 
output from the Diskhaler reached the patient - on 
average containing 1.1 mg salbutamol. Whether the 
difference in effect was due to a difference in quality 
of the dry and wet aerosols is impossible to say from 
the present study. 
The Diskhaler was designed to be clinically equiva- 
lent to the Rotahaler. This powder inhaler with very 
low resistance against airflow was reported to be 
significantly less efficient in children inhaling at PIFs 
from 3650 1 min ~ ’ compared to inhalations at PIFs 
over 60 1 min - ’ (12). Spiro et al. studied inspiratory 
flow of 19 asthmatic patients inhaling through the 
Diskhaler. The lowest PIF was 59 1 min- ’ and 
this was not correlated to the FEV, (13). We have 
previously found PIFs as low as 43 1 min ~ ’ in an 
unselected sample of 42 patients attending a chest 
clinic with only a weak correlation between PIF 
through the device and expiratory lung function (14). 
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In the present study, the Diskhaler even caused 
bronchodilation in the patient with the lowest 
recorded mean PIF through the device (37 1 min - ‘), 
and no lower limit for proper function of the device 
was detectable. The design of the Diskhaler is quite 
different from the design of the Rotahaler and the 
airflow resistance is higher. This may, in part, explain 
the efficacy of the Diskhaler at low PIFs. In the 
present study, we again found only a weak correla- 
tion between PIF through the Diskhaler and expira- 
tory lung function, making it impossible to predict 
the ability to inhale from the baseline spirometry. 
However, as the device was effective in patients with 
both low and high PIFs, this parameter is of minor 
importance in the individual patient. 
In an in vitro experiment, Hohnann et al. found 
that a constant flow of 48 1 min - ’ was necessary to 
empty the Diskhaler completely (15). Most patients 
in the present study did not reach a constant inspira- 
tory flow through the device, but it could be esti- 
mated that an inhalation with PIF=48 1 min- ’ 
would on average, have removed about 15 mg of 
powder from each blister (total amount=26 mg). 
However, application of the present high doses and 
possibly reaching the plateau of the dose-response 
curve, may also, in part, explain that bronchodilation 
was obtained even in patients with lowest PIF. 
The present study indicates that most patients with 
severe COPD can use the Diskhaler instead of a 
domiciliary nebulizer if sufficient doses of salbutamol 
are prescribed. The replacement of the nebulizer by 
a powder inhaler will allow the patient to take the 
treatment anywhere, independent of a power supply. 
Furthermore it will save time. It takes lCL15 minutes 
to nebulize 25 ml whereas a dry powder inhalation 
takes a few seconds. 
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